Variation in the pharmacokinetics of glucosamine in healthy individuals

Abstract

Objectives Clinical trial data for the efficacy of glucosamine in OA are conflicting. Reportedly, Rotta-manufactured glucosamine products are more likely to be effective, and a possible explanation is greater bioavailability than other brands. Specifically, the aim was to compare the steady-state pharmacokinetics of Rotta- and non-Rotta-manufactured glucosamine products in healthy volunteers and examine the interindividual variability. Methods In a crossover design, healthy adult participants ingested 1500 mg/day of a Rotta (DONA powder sachets; imported by Mylan Health, Carole Park, QLD, Australia) and a non-Rotta (glucosamine sulphate 1500 mg one-a-day tablet; Blackmores, Warriewood, NSW, Australia) glucosamine product/brand individually for 6 days. Blood samples were collected immediately before and for 12 h after the ingestion of the last dose of each brand and analysed to determine plasma levels of glucosamine. The pharmacokinetic parameters at steady state [including the minimum (Css min) and maximum (Css max) plasma concentration of glucosamine, time to reach Css max post-dosing (Tss max) and area under the plasma concentration vs time curve (AUCss 0–12)] for each brand were calculated and statistically compared. Results Fourteen participants [mean age 35.5 years (s.d. 8.8)] were recruited (64.2% males). No significant differences were observed in the pharmacokinetic parameters between the two brands. However, for both brands, the coefficient of variation for Css min, Tss max and AUCss 0–12 exceeded 20%, indicating considerable differences in the parameters between participants. No significant association of the pharmacokinetic parameters was observed with various dosing- and participant-related variables. Conclusion Substantial interindividual differences in the absorption and elimination of glucosamine could be a cause of variable clinical outcomes in OA. Trial registration The study was registered with the Australian New Zealand Clinical Trials Registry (http://www.ANZCTR.org.au/ACTRN12618000699268p.aspx), number ACTRN12618000699268p.

Glucosamine Enhancement of Learning and Memory Functions by Promoting Fibroblast Growth Factor 21 Production

“…Additionally, previous research involving osteoarthritis patients and normal individuals without medical conditions who received oral GLN showed significant variability in steady-state plasma concentrations. This suggests notable differences among individuals in how GLN is absorbed and eliminated [72,73]. Consequently, to develop therapies targeting FGF21 production induced by GLN for cognitive disorders, enhancing GLN's bioavailability through dosage optimization and alternative administration methods is imperative to maximize its effects.…”

The Formulation of the N-Acetylglucosamine as Nanoparticles Increases Its Anti-Inflammatory Activities: An In Vitro Study

“…Bioavailability and drug delivery are the most important causes of failure. In addition, epigenetic changes plus individual polymorphisms increase the variability of response to treatments [ 7 ]. This made it necessary to increase the drug dosage to ensure the pharmacological response.…”